Advertisement

Gastrointestinal tract perforation in dogs treated with a selective cyclooxygenase-2 inhibitor: 29 cases (2002–2003)

B. Duncan X. Lascelles BVSc, PhD, DACVS1, Anthony T. Blikslager DVM, PhD, DACVS2, Steven M. Fox DVM, PhD3, and Doug Reece DVM4
View More View Less
  • 1 Comparative Pain, Research Laboratories, Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606.
  • | 2 Gastrointestinal Biology, Research Laboratories, Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606.
  • | 3 Novartis Animal Health US Inc, 3200 Northline Ave, Greensboro, NC 27408.
  • | 4 Novartis Animal Health US Inc, 3200 Northline Ave, Greensboro, NC 27408.

Abstract

Objective—To identify factors associated with gastrointestinal tract perforation in dogs being treated with a selective cyclooxygenase-2 (COX-2) inhibitor (deracoxib).

Design—Retrospective study.

Animals—29 dogs.

Procedure—The Novartis Animal Health pharmacovigilance database was searched for records of dogs treated with deracoxib in which gastrointestinal tract perforation was documented.

Results—16 of the 29 (55%) dogs had received deracoxib at a dosage higher than that approved by the FDA for the particular indication being treated, with 25 (86%) dogs having received deracoxib at a dosage > 2 mg/kg/d (0.9 mg/lb/d). Seventeen (59%) dogs had received at least 1 other nonsteroidal anti-inflammatory drug (NSAID) or a corticosteroid in close temporal association (within 24 hours) with deracoxib administration (ie, immediately before or following). In all, 26 (90%) dogs had received deracoxib at a higher-than-approved dosage or had received at least 1 other NSAID or corticosteroid in close temporal association with deracoxib administration. Twenty dogs died or were euthanatized, and 9 survived.

Conclusions and Clinical Relevance—In dogs with gastrointestinal tract perforation and that had been treated with deracoxib, perforation was most likely attributable to a number of factors. Deracoxib should only be used at approved dosages. Cortico-steroids and other less selective NSAIDs should not be administered in close temporal association with selective COX-2 inhibitors, including deracoxib. Further study is required to define this problem. (J Am Vet Med Assoc 2005;227:1112–1117)